# NCT03486067 (NCT03486067)

> Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03486067
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: CC-93269
- Enrollment: 183
- Primary outcome: Adverse Events (AEs)
- Primary outcome: Dose Limiting Toxicity (DLT)
- Primary outcome: Non-Tolerated Dose (NTD)
- Primary outcome: Maximum Tolerated Dose (MTD)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03486067